73 peer-reviewed studies across cancer, oral, neuro, cardiovascular, autoimmune, metabolic, and reproductive health. A Nobel Prize. A $60 million state research fund. Decades of safety data. Read it yourself.
Foundational study showing FBZ destabilizes microtubules, triggers p53-mediated apoptosis, and blocks xenograft tumor growth in mice. 605,000+ accesses, 108 citations.
Phase I/II clinical trial reported a 37.5% clinical benefit rate in metastatic triple-negative breast cancer. Presented at ASCO 2025.
Comprehensive protocol combining all three compounds with dosing guidelines. Oxfendazole Phase I data confirms tolerability at doses up to 60 mg/kg.
Most sensitive: ovarian, breast, glioblastoma, lung, colon. Synergistic with docetaxel, cyclophosphamide, and tamoxifen.
800mg three times daily showed tolerability in recurrent glioblastoma patients. First clinical MBZ cancer trial data.
Oral bacterium P. gingivalis identified in postmortem AD brains. Oral infection in mice produced brain colonization and amyloid-β response — one of the strongest molecular links between oral health and neurodegeneration.
Join the beta to access the full searchable database of 73 peer-reviewed studies — filterable by drug, body system, or condition.
Join the Beta →